This inventor holds 1 USPTO granted patent. Top assignee: Ionctura Sa. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Lars Van Der Veen: Inventor in Pharmaceutical Innovation
Introduction
Lars Van Der Veen is an inventor based in Geneva, Switzerland, associated with Ionctura SA. His patent work concerns a PI3K-δ inhibitor intended for treatment regimens addressing diseases in which the PI3Kδ pathway is pathologically implicated.
Latest Patents
Van Der Veen is associated with 1 patent: “PI3K-δ inhibitor for use in treatment regimens.” The patent describes a compound, or a pharmaceutically acceptable salt thereof, for treating conditions such as cancer and inflammatory or autoimmune diseases. It specifies a dose and reports a favorable safety profile in humans, particularly regarding hepatotoxicity, diarrhea or colitis, respiratory infections, and hematologic toxicities.
Career Highlights
His listed patent reflects work on targeted pharmaceutical treatment and the safety considerations involved in developing therapies that affect PI3Kδ signaling. The available information identifies Ionctura SA as his company.
Collaborations
Catherine Pickering and Michael Lahn are identified as Van Der Veen’s coworkers. Their shared association with Ionctura SA provides context for his professional environment, though specific collaborative roles are not provided.
Conclusion
Lars Van Der Veen’s recorded invention focuses on a PI3K-δ inhibitor for treatment regimens, highlighting pharmaceutical innovation aimed at addressing serious diseases while considering patient safety.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile